Vendor Intelligence Report: Yimei
Published 12 Nov 2026. 35-page investigative report on who is behind Yimei: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Yimei/Pepturion is a split catalog, not a single-score vendor. Across 132 Finnrick lab tests, Yimei posts 107 pass / 23 fail, an 81% overall pass rate. GHK-Cu and Ipamorelin are the cleanest lanes; Retatrutide is pass-majority but mixed; NAD+ is the clearest warning lane. The report also shows how ratings move under stricter purity/fill grading.
The identity layer is materially murkier than the test headline. Marketplace records support a Yimei-to-Pepturion continuity story, but no current public record closes the legal chain behind it. UK filings point to dissolved Yimei entities and a formation-service cluster; the active UK and Dutch Pepturion stores do not publish a complete legal seller identity, company/KvK details or beneficial-owner disclosure.
COA and payment artifacts are the practical risk signal. The report documents useful Janoshik anchors alongside gaps: a CJC/Ipamorelin certificate without purity, a TB-500 claim/certificate conflict, and Tesamorelin tied to a supplier-side COA rather than a clean Pepturion lot. UK checkout uses Wise bank transfer with a beneficiary-name mismatch warning; the Dutch store offers stronger rails but still no clear merchant identity. Public QA and batch-release responsibility remains unidentified, treated as a transparency limit rather than proof of absent expertise.
Inside the full report:
- Complete Finnrick product-by-methodology breakdown, including rating-divergence and spark-grid views
- Yimei-to-Pepturion timeline built from Peptaura, RDAP, Wayback and Companies House records
- COA/claim analysis for UK and Dutch Pepturion certificates, including Janoshik task keys
- UK vs Dutch storefront, legal-notice, payment and buyer-recourse comparison
- Promotion and review-integrity review covering Trustpilot clustering, Peptaura attribution and discount-code posts
Risk assessment
- Product-specific quality risk — weak Yimei lanes — high: NAD+ 27.97%, MOTS-c 37.76%, Epithalon 39.54%, CJC-1295 45.48%, TB-500 46.88%, Tesamorelin 56.49%, BPC-157 57.65% and hCG 61.73% are weak.
- Retatrutide and tirzepatide batch-consistency risk — medium: Retatrutide is 84.24% across 53 tests (45/8) and Tirzepatide is 80.07% across 7 tests (6/1); usable only with batch discipline.
- Corporate-identity and legal-recourse risk — high: No current Pepturion UK company, no Dutch KvK/legal address, and the only directly named UK Yimei company is dissolved.
- COA and lot-traceability risk — high: Tesamorelin uses a Yinglian supplier COA with unknown manufacturer/batch; CJC/Ipamorelin has no purity result; several strengths, pens and nasals lack public batch-matched COAs.
- Payment-recourse risk — medium: The UK checkout uses irreversible bank transfer/crypto and tells buyers to ignore a beneficiary-name mismatch on a Wise GBP account.
- Brand-confusion and authenticity-verification risk — medium: Yimei/Pepturion/Peptaura continuity is hard to verify live, Peptaura Yimei is 404, and Pepturion publishes no official-channel or authorized-reseller list.
- Affiliate-promotion risk — medium: A Yimei Reta Zeus discount-code post lacked visible disclosure, PeptideStack promotes with PSTACK, and Pepturion runs a self-signup affiliate program with no captured disclosure rules.